LEO Pharma initiates the first Phase 3 clinical trial with delgocitinib cream in adult patients with moderate-to-severe chronic hand eczema (CHE)
NOT FOR DISTRIBUTION IN THE UK OR IRELAND BALLERUP, Denmark, 18 May 2021 -- LEO Pharma A/S, a global leader in medical dermatology, today announced it has enrolled the first adult patient in the first of two pivotal Phase 3 clinical trials with delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor, for the potential treatment of adult patients with moderate-to-severe chronic hand eczema (CHE).
Delgocitinib inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.[i],[ii] The cream formulation of delgocitinib is an investigational therapy under clinical development and has not been approved by any regulatory authority.
The primary objective for the randomized, double-blind, vehicle-controlled, multi-center Phase 3 clinical trials (DELTA 1 and DELTA 2) is to evaluate the efficacy of twice-daily applications of delgocitinib cream 20 mg/g compared with vehicle in the treatment of adults with moderate-to-severe CHE.[iii],[iv]
The primary endpoint of the trials is the Investigator’s Global Assessment for chronic hand eczema treatment success (IGA-CHE TS) at Week 16.3,4 Treatment success is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with at least a two-step improvement from baseline.3,4
Key secondary endpoints at Week 16 include reduction of itch and pain scores of ≥4 points measured by the Hand Eczema Symptom Diary (HESD) from baseline to Week 16,3,4 as well as at least 75% improvement from baseline and at least 90% improvement from baseline on the Hand Eczema Severity Index (HECSI) at Week 16.3,4 The number of treatment-emergent adverse events per patient from baseline to Week 16 defines the key safety endpoint of the trials.3,4
"Managing moderate-to-severe CHE is challenging because of limited available treatment options for chronic use,” said Dr. Sibylle Schliemann, Consultant, Department of Dermatology, University Hospital Jena, Germany and lead investigator for DELTA 2. “These trials will evaluate whether delgocitinib cream can potentially offer a new treatment option for adult patients with moderate-to-severe CHE who suffer from a considerable burden of disease.”
CHE is defined as hand eczema (HE) that lasts for more than three months or relapses twice or more within a year.[v],[vi] HE is the most common skin disorder of the hands[vii] that affects an estimated 1 – 5% of the general population[viii] with a one-year prevalence rate of approximately 10%.[ix] It is an inflammatory, non-infectious skin disorder of the hands and wrists5,[x]and can cause itching, blisters, swelling and pain so severe that it can impair the ability to work.5,7,[xi]In a substantial number of patients, HE can develop into a chronic condition.7
“We have been encouraged by the positive results from the Phase 2b CHE clinical trial with delgocitinib cream and look forward to learning whether it has the potential to offer benefits to adult patients through a larger Phase 3 clinical development program,” said Dr. Jörg Möller, Executive Vice President, Global Research & Development, LEO Pharma. “We are committed to developing innovative therapies that may help improve the lives of patients who need more treatment options for skin diseases.”
[i] Damsky W, and King BA. JAAD; 2017;76(4):736-744.
[ii] Virtanen AT, et al. BioDrugs. 2019;33:15–32.
[iii] ClinicalTrials.Gov: https://clinicaltrials.gov/ct2/show/NCT04871711?term=delgocitinib&draw=1&rank=8 (Accessed May 2021).
[iv] ClinicalTrials.Gov: https://clinicaltrials.gov/ct2/show/NCT04872101?term=delgocitinib&draw=1&rank=7 (Accessed May 2021).
[v]Lynde C, et al. J Cutan Med Surg. 2010;14:267–84.
[vi]Diepgen TL, et al. J Dtsch Dermatol Ges. 2015 Jan;13(1):e1–22. doi: 10.1111/ddg.12510_1.
[vii] Bissonnette R, et al. JEADV. 2010;24;1–20.
[viii] Christoffers WA, et al. Cochrane Database Syst Rev. 2019;4:CD004055.
[ix] Thyssen, et al. Contact Dermatitis. 2010;62:75-87.
[x]Menné T, et al. Contact Dermatitis. 2011;65:3–12.
[xi]Politiek K, et al. Contact Dermatitis. 2016;75:67–76.
Global Product Communications
+1 973 908 7924
Global External Communications
+45 3140 6180
About LEO Pharma
In 2014, LEO Pharma A/S and Japan Tobacco Inc. (JT) entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib for topical use in dermatological indications worldwide, excluding Japan, where JT retains rights.
In 2020, LEO Pharma completed a multi-center, randomized Phase 2b dose-finding clinical trial with twice-daily topical delgocitinib cream for the treatment of adults with mild-to-severe CHE. The company presented top-line results of the trial at the European Academy of Dermatology and Venereology (EADV) Virtual 2020[i] and presented the results of HECSI measurements during the trial at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX) 2021.[ii]
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries. In 2020, the company generated net sales of DKK 10,133 million. For more information please visit www.LEO-Pharma.com.
[i] Worm M, et al. The topical pan-JAK inhibitor delgocitinib cream demonstrates dose response in a 16-week phase 2b trial in chronic hand eczema. Presented during the Late Breaking News session of the European Academy of Dermatology and Venereology (EADV) Virtual 2020 on 29 October 2020.
[ii] Soerensen P, et al. A phase 2b trial evaluating the efficacy of delgocitinib cream for the treatment of chronic hand eczema (CHE) using and validating the Hand Eczema Severity Index (HECSI). E-poster presented at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX) 23-25 April 2021.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma receives positive CHMP opinion of Adtralza® (tralokinumab) for the treatment of adults with moderate-to-severe atopic dermatitis23.4.2021 12:32:53 CEST | Press release
• If authorized, Adtralza® (tralokinumab) will be the first approved biologic that specifically targets the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms1,2 • The CHMP opinion is primarily supported by data from ECZTRA 1, 2, and 3 trials included in the Marketing Authorization Application
LEO Fondet og Nordic Capital indgår nyt partnerskab, der skal styrke LEO Pharma23.3.2021 13:00:00 CET | Pressemeddelelse
Nordic Capital, en førende global investor inden for sundhedsområdet, bliver partner med LEO Fondet og træder ind i LEO Pharma som aktiv minoritetsejer, der skal understøtte LEO Pharmas rejse mod globalt lederskab inden for medicinsk dermatologi og bidrage til at accelerere innovation og vækst. LEO Fondet er fortsat virksomhedens majoritetsejer.
LEO Pharma delivered on strategic ambitions and showed resilience during COVID-19 pandemic in 202023.3.2021 13:00:00 CET | Press release
Ballerup, Denmark, March 23, 2021. LEO Pharma net sales recovered from COVID-19 impact during the year, reaching DKK 10.1 billion (-6%) Strategic psoriasis products Enstilar® and Kyntheum® continued to grow and gain market share. Total revenue declined 1.8% when excluding discontinued or divested products. This was offset by the impact of coronavirus lockdowns, generics in Europe and further price pressure in the US. - Revenue of Enstilar® increased 3% (+10% in Europe) to DKK 1,125 million, compared to topical market declining 2% - Revenue of Kyntheum® increased 40% to DKK 467 million compared to market growth of biologics for psoriasis of 16% Strategic projects progressed as planned while LEO Pharma ensured business continuity In response to the coronavirus pandemic, LEO Pharma successfully implemented a plan to ensure safety and corporate responsibility, continuity of supply, and continuity of strategic projects. - Supply chain and clinical trials continued uninterrupted - Introduced
LEO Pharma strengthens global leadership team with appointment of Jörg Möller as Executive Vice President, Global Research and Development16.12.2020 12:15:37 CET | Press release
Ballerup, December 16, 2020 – LEO Pharma A/S today announced that Jörg Möller will join its Global Leadership Team as Executive Vice President, Global Research and Development, effective January 1, 2021. Möller joins LEO Pharma from Bayer Pharma, where he has been EVP Head of R&D and Member of the Bayer Pharma Executive Committee. A medical doctor and Ph.D. by training, Jörg Möller brings a wealth of experience from his long international career during which he was responsible for a significant global organization with main hubs in Germany, the US, Switzerland, Japan and China. He led the entire value chain from target and drug discovery through clinical development, life-cycle-management and regulatory approvals and has brought a range of successful global product approvals. His experience spans multiple therapeutic areas including dermatology and immunology and a variety of technology platforms like biologics and cell & gene therapies. He has a solid track record of working with exte
LEO Pharma completes sale of portfolio of four products to Cheplapharm15.12.2020 13:20:01 CET | Press release
BALLERUP, Denmark, December 15, 2020 – Today, LEO Pharma A/S announced that the sale of a portfolio of four non-core products to Cheplapharm for approximately EUR 300 million has been complet-ed. The agreement was announced on August 31, 2020.
LEO Pharma launches #everydaypsoriasis campaign to mark World Psoriasis Day28.10.2020 08:05:00 CET | Press release
BALLERUP, Denmark, October 28, 2020 - LEO Pharma A/S today marked World Psoriasis Day by launching a series of videos featuring patients that outline the everyday challenges of living with psoriasis. The #everydaypsoriasis videos give personal perspectives on the challenges of living with psoriasis. To accompany the patient videos, LEO Pharma staff from around the world filmed a manifesto during COVID home-working restrictions, outlining their everyday commitment to supporting patients with psoriasis: WATCH OUR MANIFESTO VIDEO HERE The #everydaypsoriasis campaign video. More information can be found at www.everydaypsoriasis.com The LEO Pharma campaign is in support of the annual International Federation of Psoriasis Associations (IFPA) World Psoriasis Day. This annual awareness day is dedicated to people living with psoriasis or psoriatic arthritis and is aimed at spreading information and raising the profile of these debilitating diseases. October 2020 marks the second year of a three
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom